5-(2-氟苯基)-环己烷-1,3-二酮 | 102821-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-(2-氟苯基)-环己烷-1,3-二酮
• 英文名称: 5-(2-fluorophenyl)-cyclohexane-1,3-dione
• 英文别名: 5-(2-fluorophenyl)-1,3-cyclohexanedione；5-(2-Fluorophenyl)cyclohexane-1,3-dione
• CAS: 102821-72-7
• 化学式: C₁₂H₁₁FO₂
• 分子量: 206.217
• InChiKey: RMEWCTHODLROAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-氟苯基)-环己烷-1,3-二酮 生成 5-(2-Fluoro-5-nitrophenyl)-cyclohexane-1,3-dione
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氟苯甲醛 在 sodium ethanolate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 36.0h， 生成 5-(2-氟苯基)-环己烷-1,3-二酮
  参考文献：
  名称：

  Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells

  摘要：

  Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. Currently, there is only one FDA-approved treatment for ALS (riluzole), and that drug only extends life, on average, by 2-3 months. Mutations in Cu/Zn superoxide dismutase (SOD1) are found in familial forms of the disease and have played an important role in the study of ALS pathophysiology. On the basis of their activity in a PC12-G93A-YFP high-throughput screening assay, several bioactive compounds have been identified and classified as cyclohexane-1,3-dione (CHD) derivatives. A concise and efficient synthetic route has been developed to provide diverse CHD analogs. The structural modification of the CHD scaffold led to the discovery of a more potent analog (26) with an EC(50) of 700 nM having good pharmacokinetic properties, such as high solubility, low human and mouse metabolic potential, and relatively good plasma stability. It was also found to efficiently penetrate the blood-brain barrier. However, compound 26 did not exhibit any significant life span extension in the ALS mouse model. It was found that, although 26 was active in PC12 cells, it had poor activity in other cell types, including primary cortical neurons, indicating that it can penetrate into the brain, but is not active in neuronal cells, potentially due to poor selective cell penetration. Further structural modification of the CHD scaffold was aimed at improving global cell activity as well as maintaining potency. Two new analogs (71 and 73) were synthesized, which had significantly enhanced cortical neuronal cell permeability, as well as similar potency to that of 26 in the PC12-G93A assay. These CHD analogs are being investigated further as novel therapeutic candidates for ALS. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.039

文献信息

• Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06350749B1

  公开（公告）日：2002-02-26

  The present invention is to provide a compound of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic heterocyclic ring, the ring B an optionally substituted 5- to 6-membered aromatic homocyclic ring or an optionally substituted 5- to 6-membered aromatic heterocyclic ring, R1 is a hydrogen atom, a hydroxy group or a lower alkyl group, and n is 0 or 1, or a salt thereof, which is effective for the prevention or treatment of ischemic cardiac disease, etc., and which is useful as an agent for preventing or treating ischemic cardiac disease, etc. such as myocardial infarction, arrhythmia, etc.

  本发明提供了一种化合物的公式：其中环A是可选地取代的5至6成员芳香杂环，环B是可选地取代的5至6成员的芳香同环或可选地取代的5至6成员的芳香杂环，R1是氢原子，羟基或低烷基，n是0或1，或其盐，该盐对于预防或治疗缺血性心脏病等有效，并可作为预防或治疗缺血性心脏病等的药物，例如心肌梗死、心律失常等。
• QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS
  申请人：Courtney Stephen Martin

  公开号：US20110118258A1

  公开（公告）日：2011-05-19

  Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

  通式（I）的化合物；或其立体异构体、互变异构体、药学上可接受的盐或前药，其中R1、R2、R3、R4、R5、R6、R8和R9如本文所定义，对于治疗由过度或不恰当的Hsp90活性介导的疾病和病况，如癌症、病毒感染和炎症性疾病或病况，是有用的。
• Cinchona Squaramide‐Catalyzed Intermolecular Desymmetrization of 1,3‐Diketones Leading to Chiral 1,4‐Dihydropyridines
  作者：Maciej Dajek、Agnieszka Pruszczyńska、Krzysztof A. Konieczny、Rafał Kowalczyk

  DOI：10.1002/adsc.202000455

  日期：2020.9.8

  Addition of prochiral cyclic 1,3‐diketones to Michael acceptors applying bifunctional Cinchona‐derived squaramides resulted in chiral adducts with stereoselectivities of up to 99% ee and allowed for desymmetrization of the nucleophile. These labile hemiacetal intermediates were transformed to new 1,4‐dihydropyridines with high diastereoselectivities and no erosion of optical purity. Their further oxidation

  在使用双官能金鸡纳衍生的方酰胺的迈克尔受体上添加前手性环状1,3-二酮会导致手性加合物的立体选择性高达99％ee，并允许亲核试剂脱对称。这些不稳定的半缩醛中间体被转化为新的1,4-二氢吡啶，具有高非对映选择性，且不会破坏光学纯度。它们进一步氧化为吡啶，然后进行费舍尔吲哚化，提供了手性吡啶吲哚。
• Cyclohexenone derivatives and their use for controlling undesirable
  申请人：BASF Aktiengesellschaft

  公开号：US04692553A1

  公开（公告）日：1987-09-08

  Cyclohexenone derivatives of the formula ##STR1## where R.sup.1 is hydrogen, methoxycarbonyl, ethoxycarbonyl, methyl or cyano, R.sup.2 is alkyl, R.sup.3 is alkyl, alkenyl, haloalkenyl, or propargyl, R.sup.4 is hydrogen or alkyl, R.sup.5 is hydrogen, alkyl, acyl, formyl, cycloalkylcarbonyl, methoxyalkylcarbonyl, unsubstituted or substituted benzoyl, alkoxycarbonyl, benzyloxycarbonyl, phenoxycarbonyl, alkylthiocarbonyl, N,N-dialkylcarbamyl, N-alkylcarbamyl, N-cycloalkylcarbamyl, N-alkoxy-N-alkylcarbamyl, unsubstituted or substituted N-phenylcarbamyl, alkylsulfonyl, alkenylsulfonyl, haloalkylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-acyl-N-alkylsulfamyl, N-alkyl-N-methoxycarbonylsulfamyl, dialkoxyphosphoryl, dialkoxythiophosphoryl, 2-haloalkanoyl, acyloxyacetyl or alkoxyoxalyl, and R.sup.6 is alkyl, halogen, hydroxyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, nitro or amino, and salts of these compounds, and the use of these compounds for controlling unwanted plant growth.

  化学式为##STR1##的环己烯酮衍生物，其中R.sup.1是氢、甲氧羰基、乙氧羰基、甲基或氰基，R.sup.2是烷基，R.sup.3是烷基、烯基、卤代烯基或丙炔基，R.sup.4是氢或烷基，R.sup.5是氢、烷基、酰基、甲酰基、环烷基羰基、甲氧基烷基羰基、未取代或取代苯甲酰基、烷氧羰基、苄氧羰基、苯氧羰基、烷基硫酰基、烯基硫酰基、卤代烷基硫酰基、N，N-二烷基氨基甲酰基、N-烷基氨基甲酰基、N-环烷基氨基甲酰基、N-烷氧-N-烷基氨基甲酰基、未取代或取代N-苯基氨基甲酰基、烷基磺酰基、烯基磺酰基、卤代烷基磺酰基、N-烷基磺酰胺基、N，N-二烷基磺酰胺基、N-酰基-N-烷基磺酰胺基、N-烷基-N-甲氧羰基磺酰胺基、双烷氧基磷酰基、双烷氧基硫代磷酰基、2-卤代烷酰基、酰氧乙酰基或烷氧草酰基，R.sup.6是烷基、卤素、羟基、烷氧基、烯基氧基、炔基氧基、烷基硫基、烷基亚磺酰基、烷基磺酰基、硝基或氨基，以及这些化合物的盐，并且这些化合物用于控制不良植物生长。
• Quinazolin-oxime derivatives as Hsp90 inhibitors
  申请人：Courtney Stephen Martin

  公开号：US08592430B2

  公开（公告）日：2013-11-26

  Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

  通式（I）的化合物；或其立体异构体、互变异构体、药学上可接受的盐或前药，其中R1、R2、R3、R4、R5、R6、R8和R9的定义如本文所述，可用于治疗由过度或不适当的Hsp90活性介导的疾病和病症，如癌症、病毒感染和炎症性疾病或病症。